Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Andrew Sharabi
University of California, San Diego, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Toragen, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sharabi is the founder, President and CEO of Toragen and holds (b)(4) equity valued at (b)(4). Toragen is focused on repurposing Rimantadine as a single generic drug for an anti-cancer indication. This grant is to establish the role of B-cell medicated IgG anti-tumor antibody responses in head and neck squamous cell carcinoma (HNSCC) and develop inhibitors of human papilloma virus (HPV) mediated immunosuppression to enhance response rates to checkpoint blockade immunotherapy (CBI). Per Dr. Sharabi, aim 2C of the grant is studying combinations of Rimantadine with radiation therapy and immunotherapy, therefore the results of aim 2C may indirectly be beneficial to Toragen. Further, Dr. Sharabi advises that they are using the Rimantadine technology but not developing it any further in his lab.
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC
Narrative The proposed research is relevant to public health because it will develop strategies to improve response rates to checkpoint blockade immunotherapy (CBI) in patients with head and neck squamous cell carcinoma (HNSCC). Our overall objective is to establish the role of B-cell mediated IgG anti-tumor antibody responses in HNSCC and develop inhibitors of human papilloma virus (HPV) mediated immunosuppression to enhance response rates to CBI. Ultimately our efforts will significantly improve our understanding of the immunological effects of radiation and CBI on B-cell immune responses in HNSCC; uncover Rimantadine as a novel anti- cancer drug which blocks HPV E5 mediated resistance to CBI in HNSCC; and establish whether B-Cell IgG responses are a novel biomarker which correlate with responses and overall survival in patients with HNSCC.
Filed on April 12, 2019.
Tell us what you know about Andrew Sharabi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.